Crowdonomics
This isn’t Regen BioPharma Inc’s most recent raise. Reg A+ · Equity · Dec 2025 (Open) is more current.View latest round
Regen BioPharma Inc

Reg A+ · Equity · Sep 2024

ClosedReg A+Equity
via the platform · last checked Oct 3, 2026
Raised
$58.2K / $2M max
3% of ceiling
Investors
—
—
Estimated pre-money
$3M
—

Financials disclosed in this offering

FY2023 · hover for source
$127K
$1.2M
FY2023
RevenueNet income
Metric
FY2023 audited
Income statement
Revenue
$126,560
Cost of goods sold
$654,749
Gross margin
-417%
Net income
$1,156,507
Balance sheet
Cash
$121,037
Accounts receivable
$0
Total assets
$353,617
Short-term debt
$95,710
Long-term debt
$0
Total liabilities
$5,457,617
Other
Headcount
1

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

3 amendments
  1. Mar 3, 2025
    • Price $0.04 → $0.03
    • Securities offered 10,000,000 → 16,666,667
    Form 1-A POS on EDGAR ↗
  2. Nov 21, 2024
    • Price $0.2 → $0.04
    Form 1-A/A on EDGAR ↗
  3. Oct 28, 2024
    Amended during SEC review — offering terms unchanged
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$3M
Price / share$0.20
Shares offered10,000,000

Estimated, not stated: $0.20 × 15,176,437 securities outstanding.

Down round. Priced 63% below Private Offering (2024) (Sep 2023): $0.20 vs $0.544 a share in today's terms.

Offering details

Target—
Max$2,000,000
Min investment—
OpenedSep 16, 2024
Deadline—
ClosedAug 29, 2025
Days active347

Links & provenance

Source: SEC EDGAR
0001493152-24-036321
Last synced Oct 3, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.